A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

被引：1
|
作者：
Ross, David M. [1 ]
Arbelaez, Alejandro [2 ]
Chee, Lynette C. Y. [3 ]
Fong, Chun Yew [4 ]
Hiwase, Devendra [5 ]
Kannourakis, George [6 ]
Kwan, John [7 ]
Liang, James [8 ]
Puliyayi, Anish [9 ]
Rose, Hannah [10 ]
Tan, Shuhying [11 ]
Teh, Tse-Chieh [12 ]
esterman, David Alan [13 ]
Wight, Joel
Rovaldi, Chris
Furutani, Elissa M.
Gaggi, Adrienne
Jiang, Ying
Lachey, Jenn
Natarajan, Harveen Dhillon
Ordonez, Claudia
机构：
[1] Flinders Med Ctr & Univ, Dept Haematol, Adelaide, SA, Australia
[2] Tweed Hosp, Brisbane, Qld, Australia
[3] Peter MacCallum Canc Ctr & Royal Melbourne Hosp, Dept Clin Haematol & Bone Marrow Transplant Serv, Melbourne, Vic, Australia
[4] Austin Hlth & Olivia Newton John Canc Res Inst, Dept Clin Haematol, Melbourne, Australia
[5] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia
[6] Ballarat Onc & Hem Serv, Ballarat, Vic, Australia
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Middlemore Hosp, Auckland, New Zealand
[9] Barwon Hlth, Geelong, Vic, Australia
[10] Box Hill Hosp, Victoria, Australia
[11] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
[12] Townsville Univ Hosp, NS Biopharma Marblehead MA, Townsville, Qld, Australia
[13] Keros Therapeut, Lexington, MA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147335
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3675
引用
收藏
页码：3675 / +
页数：5
相关论文
共 50 条
  • [21] A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
    Howard, Jo
    Hemmaway, Claire Jane
    Telfer, Paul
    Layton, D. Mark
    Porter, John
    Awogbade, Moji
    Mant, Timothy
    Gretler, Daniel D.
    Dufu, Kobina
    Hutchaleelaha, Athiwat
    Patel, Mira
    Siu, Vincent
    Dixon, Sandra
    Landsman, Noel
    Tonda, Margaret
    Lehrer-Graiwer, Joshua
    BLOOD, 2019, 133 (17) : 1865 - 1875
  • [22] Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
    Garcia-Manero, Guillermo
    Roboz, Gail
    Walsh, Katherine
    Kantarjian, Hagop
    Ritchie, Ellen
    Kropf, Patricia
    O'Connell, Casey
    Tibes, Raoul
    Lunin, Scott
    Rosenblat, Todd
    Yee, Karen
    Stock, Wendy
    Griffiths, Elizabeth
    Mace, Joseph
    Podoltsev, Nikolai
    Berdeja, Jesus
    Jabbour, Elias
    Issa, Jean-Pierre J.
    Hao, Yong
    Keer, Harold N.
    Azab, Mohammad
    Savona, Michael R.
    LANCET HAEMATOLOGY, 2019, 6 (06): : E317 - E327
  • [23] High-dose rHuEPO for the treatment of patients with low-risk myelodysplastic syndromes
    Latagliata, R.
    Oliva, E.
    Volpicelli, P.
    Napoleone, L.
    Carmosino, I.
    Breccia, M.
    Stefanizzi, C.
    Vincelli, I.
    Alati, C.
    Vozella, F.
    Nobile, F.
    Alimena, G.
    LEUKEMIA RESEARCH, 2009, 33 : S121 - S121
  • [24] A phase 2, ascending dose study of ACE-536 to treat anemia in low/intermediate-1 risk MDS patients: The PACE-MDS study
    Platzbecker, U.
    Attie, K.
    Wilson, D.
    Boyd, I.
    Germing, U.
    Goetze, K.
    Giagounidis, A.
    Kiewe, P.
    Mayer, K.
    Ottman, O.
    Radsak, M.
    Wolff, T.
    Sherman, M.
    LEUKEMIA RESEARCH, 2013, 37 : S167 - S167
  • [25] Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)
    Jabbour, Elias
    Sasaki, Koji
    Daver, Naval
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Kadia, Tapan
    Miller, Darla
    Sukholutsky, Victoria
    Huang, Xuelin
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [26] A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result
    Chuncharunee, Suporn
    Kanitsap, Nonglak
    Suwanban, Tawatchai
    Khuhapinant, Archrob
    Uaprasert, Noppacharn
    Chansung, Kanchana
    Rattarittamrong, Ekarat
    Wongkhantee, Somchai
    Siritanaratanakul, Noppadol
    Norasetthada, Lalita
    Nakorn, Thanyaphong Na
    Charnwiboonsri, Chadchai
    BLOOD, 2016, 128 (22)
  • [27] Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
    Platzbecker, Uwe
    Germing, Ulrich
    Goette, Katharina S.
    Kiewe, Philipp
    Mayer, Karin
    Chromik, Joerg
    Radsak, Markus
    Wolff, Thomas
    Zhang, Xiaosha
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    Giagounidis, Aristoteles
    LANCET ONCOLOGY, 2017, 18 (10) : 1338 - 1347
  • [28] Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial
    Moser, Miriam M.
    Thalhammer, Renate
    Sillaber, Christian
    Derhaschnig, Ulla
    Firbas, Christa
    Jaeger, Ulrich
    Jilma, Bernd
    Schoergenhofer, Christian
    FRONTIERS IN MEDICINE, 2024, 11
  • [29] Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study
    Paparrigopoulos, Thomas
    Tzavellas, Elias
    Karaiskos, Dimitris
    Kourlaba, Georgia
    Liappas, Ioannis
    BMC PSYCHIATRY, 2011, 11
  • [30] Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
    Adem T. Can
    Daniel F. Hermens
    Megan Dutton
    Cyrana C. Gallay
    Emma Jensen
    Monique Jones
    Jennifer Scherman
    Denise A. Beaudequin
    Cian Yang
    Paul E. Schwenn
    Jim Lagopoulos
    Translational Psychiatry, 11
12345